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Available online 29 June 2016Background:Vaso-occlusive crisis (VOC), hallmark of sickle-cell disease (SCD), is the ﬁrst cause of patients' Emer-
gency-Room admissions and hospitalizations. Acute chest syndrome (ACS), a life-threatening complication, can
occur during VOC, be fatal and prolong hospitalization. No predictive factor identiﬁes VOC patients who will de-
velop secondary ACS.
Methods: This prospective, monocenter, observational study on SS/S-β0thalassemia SCD adults aimed to identify
parameters predicting ACS at Emergency-Department arrival. The primary endpoint was ACS onset within
15 days of admission. Secondary endpoints were hospitalization duration, morphine consumption, pain evalua-
tion, blood transfusion(s) (BT(s)), requiring intensive care and mortality.
Findings: Among 250 VOCs included, 247 were analyzed. Forty-four (17.8%) ACSs occurred within 15 (median
[IQR] 3 [2, 3]) days post-admission based on auscultation abnormalities; missing chest radiographs excluded
three patients. Comparing ACS to VOC, respectively, median hospital stay was longer 9 [7–11] vs 4 [3–7] days
(p b 0.0001), 7/41 (17%) vs 1/203 (0.5%) required intensive care (p b 0.0001), and 20/41 (48.7%) vs 6/203 (3%)
required BTs (p b 0.0001). No patient died. The multivariate model retained reticulocyte and leukocyte counts,
and spine and/or pelvis pain as being independently associated with ACS; the resulting ACS-predictive score's
area under the ROC was 0.840 [95% CI 0.780–0.900], 98.8% negative-predictive value and 39.5% positive-predic-
tive value for the real ACS incidence.
Interpretation: The ACS-predictive score is simple, easily applied and could change VOCmanagement and thera-
peutic perspectives. Assessed ACS risk could lead to earlier discharges or close monitoring and rapid medical in-
tensiﬁcation to prevent ACS.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Sickle cell disease
Vaso-occlusive crisis
Acute chest syndrome
Score
Prospective study1. Introduction
Vaso-occlusive crisis (VOC), hallmark of sickle-cell disease (SCD), is
the primary cause of Emergency-Department admissions and patients'
hospitalizations (Ballas and Lusardi, 2005). About 20% of all-age deaths
in the United States occurred during VOCs, and more frequently for
those 20–54 years old in an inpatient facility (Hamideh and Alvarez,dicine, Henri-Mondor Hospital,
rance.
i).
. This is an open access article under2013). Secondary acute chest syndrome (ACS), the main severe VOC
complication (Platt et al., 1994; Perronne et al., 2002), represented
50% of ACSs in a prospective study, appearing a mean of 2.5 days post-
admission for VOC (Vichinsky et al., 2000). ACS remains a major cause
of SCD-associated adult mortality (Platt et al., 1994; Perronne et al.,
2002; Vichinsky et al., 2000; Maitre et al., 2000) and a major risk factor
for early death (Platt et al., 1994). ACS is also associated with shortened
survival probability, even long after the episode (Castro et al., 1994),
particularly in conjunction with acute pulmonary hypertension
(Mekontso Dessap et al., 2008). Still, prospective studies on adult
VOCs are rare. Ballas et al., who studied 117 VOCs in 36 SCD patientsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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locyte counts, lactate dehydrogenase (LDH) levels and inﬂammatory
markers at the initial VOC phase vs steady state. In another study, half
of the 102 patients studied had a prodromal phase 1–2 days pre-hospi-
talization, after the following precipitating factors, in decreasing fre-
quency: cold, exertion, tiredness, infection, stress or worry,
dehydration, alcohol consumption and pregnancy (Murray and May,
1988).
However, no study has yet focused on differences at admission be-
tween VOC patients whowill or will not develop ACS. Predictive clinical
and biological markers could provide important information on VOC
and ACS pathophysiologies needed to develop new therapeutic targets.
Moreover, a score predicting ACS could generate innovative strategies
to prevent ACS and/or simplify low-risk VOCmanagement, thereby lim-
iting morbidity and mortality, and shortening hospitalizations.
This predictive severity (PRESEV) study was undertaken to identify
VOC-risk factors and construct a score predicting ACS at Emergency-De-
partment arrival for VOC.
2. Patients and Methods
2.1. Participants
This prospective, monocenter, observational study included SS or S-
β0thalassemia patients, ≥18 years old arriving at the Emergency Room
with severe VOC requiring hospitalization in our university hospital's
Adult Sickle-Cell Referral Center. Severe VOCwas deﬁned as pain or ten-
derness not controlled by grade-II analgesics (codeine or tramadol), af-
fecting at least onepart of the body, ie, limbs, ribs, sternum, head (skull),
and spine and/or pelvis (S ± P), that required opioids and was not at-
tributable to other causes. Exclusion criteria included: VOC with paren-
teral hydration lasting N24 h (because 24 h of treatment could modify
clinical and biological parameters), primary ACS, transfusion or blood-
exchange transfusion (henceforth referred to as BT) during the preced-
ingmonth or chronic BTs, previous delayed hemolysis-transfusion reac-
tion making BT impossible, severe complication requiring BT at arrival,
pregnancy, psychiatric disorder, proven sepsis and/or surgery
b15 days earlier. Patients with multiple hospitalizations separated by
≥1 month could be enrolled in the trial more than once if each episode
satisﬁed inclusion criteria.
Standardized care included bed rest, ﬂuid replacement with 5% glu-
cose (2 L with 4 g of NaCl/L), oral alkaline water (500 mL/day), folinic
acid (5 mg/day), intravenous paracetamol (1 g every 6 h), at least 2 L
of O2/min to obtain 98% transcutaneous oxygen saturation (SpO2) and
systematic preventive incentive spirometry. Hydroxyurea therapy was
noted. Morphine was administered by patient-controlled analgesia, ac-
cording a standardized procedure. For febrile (N38 °C) patients,
hemoculture and urinalysis (CBEU)were run; Legionella and streptococ-
cal pneumonia urinary antigens were sought when an auscultatory ab-
normality or radiological inﬁltrate was present. Empirical antibiotic
therapy (amoxicillin and/or macrolide for suspected allergy or intracel-
lular bacteria) was prescribed. French guidelines deﬁned BT indications
(Perronne et al., 2002). To assure the reliability of specimen sampling,
storage and analysis, patients arriving at the Emergency Department
after midnight were included the next morning except weekends, and
hospitalized in the Internal Medicine or Clinical Immunology Depart-
ment specialized in SCDmanagement (after January 2008). Transfusion
indications according to French guidelines (Lionnet et al., 2009) were:
anemia b6/dL with symptoms, VOC lasting N8 days without improve-
ment, every acute severe complication, overt stroke, severe infection,
multiorgan involvement, acute priapism lasting N3 h and severe ACS.
The latter was deﬁned by one of the following: respiratory frequency
N30/min or b10/min not related to opioid overdose, shallow breathing,
breathlessness on speaking, impaired consciousness, important exten-
sion of auscultatory abnormality and/or radiological inﬁltrate, arterial
blood–gas PO2 b 60 mm Hg.2.2. Primary and Secondary Endpoints
VOC and ACS groups were formed. The primary endpoint was ACS
onset within 15 days of admission, deﬁned as the appearance of an aus-
cultatory abnormality (crepitants and/or bronchial breathing) and/or
chest pain and an inﬁltrate on chest ﬁlm and/or thoracic computed-to-
mography (CT) scan but excluding atelectasia. Secondary endpoints
were: hospitalization duration, BT, morphine consumption, visual ana-
log scale (VAS: 0 mm, none; 100 mm, worst possible) for pain and our
categorical pain score (CPS: range 0–3 points: 0, no pain; 1, mild pain,
unaffected by mobilization; 2, moderate pain, increased by mobiliza-
tion; 3, severe pain with disability) (Bartolucci et al., 2009) evaluations,
BT, intensive care unit admission and mortality. Medical history and
precipitating factors were systematically recorded on a standardized
form.
Each patient's clinical and biological parameters were determined at
arrival. Every patient was examined by two physicians at least twice
daily (for independent determinations of auscultatory abnormality),
and nurses recorded temperature, pain, SpO2, respiratory and cardiac
frequencies at least every 6 h. For the CPS, patients graded their pain
in seven body sites (all four limbs, ribs and sternum, head, and S ± P;
Fig. 1). Chest radiograph or thoracic CT scanwas obtained for an auscul-
tatory abnormality and/or chest pain. A radiologist and Referral Center
physician blindly analyzed images. Daily morphine consumption was
recorded on hospitalization days 1, 2 and 4. Patients could bedischarged
once painwas controlled by grade-II analgesics. All patients consulted at
steady state, deﬁned as ≥1 month post-hospitalization for VOC, infec-
tion, ACS, any other clinical event necessitating hospitalization and/or
BT, and ≥3 months after the last BT, with biological parameter
determinations.
Our local Ethics Committee (CPP Île-de-France IX) approved this
study, conducted in accordance with the Declaration of Helsinki, Good
Clinical Practice guidelines, and local laws and regulations. Patients
were enrolled after giving their written informed consent.
2.3. Statistical Analyses
To detect relevant major biological parameter differences with 80%
power and a 5% alpha risk, 250 inclusions including 20% ACSs were re-
quired (e.g., differences of 1 g of hemoglobin/dLwith standard deviation
(SD)=2with unequal variance) and 40× 109 reticulocytes/L (SD=80,
with unequal variance).
Continuous variables are expressed asmeans±1 SD ormedians [in-
terquartile range], depending on their normal or asymmetric distribu-
tions. Categorical variables are expressed as numbers (%). ACS-
associated factors were ﬁrst sought by univariate analyses, using
Student's t-test or Mann–Whitney non-parametric test, depending on
the distribution, or χ2 or Fisher's exact test, where appropriate. Analysis
of variance for repeated measures compared morphine doses on the
ﬁrst 4 days of hospitalization. Continuous variables signiﬁcantly associ-
ated with ACS were transformed into binary variables, based on whole-
populationmedians and conﬁrmed by receiver operating characteristics
(ROC) curve-determined thresholds. ACS-associated factors (p ≤ 0.05)
were entered into logistic-regressionmodels with a backward-stepwise
procedure, conﬁrmed by a forward procedure adjusted to two day-1 he-
moglobin-level classes. Variables achieving p ≤ 0.05 were kept in the
model. Goodness-of-ﬁt was assessed with the Hosmer–Lemeshow test
and improvement by the ﬁnal model of the explained variability by
Nagelkerke's R2.
Each patient's ACS-predictive score was calculated using rounded
linear transformation of the model coefﬁcients and a binary value, 0/1,
for the respective absence/presence of the event. The predictive score's
performance was assessed with ROC curves and calculation of the area
under them (AUROC) and its 95% conﬁdence interval (CI). The threshold
best discriminating between 2°ACS and VOCwas retained, based on the
score's highest sensitivity and negative-predictive value (NPV).
Fig. 1. Frequency of spine-and/or-pelvis categorical pain score determination at Emergency-Department arrival.
307P. Bartolucci et al. / EBioMedicine 10 (2016) 305–311Sensitivity analysis used a third reticulocyte-count category for patients
with missing data. All statistical analyses were computedwith SPSS v18
and/or Stata v11 software.
3. Results
3.1. Patients and Inclusion Characteristics
Recruitment lasted from July 2006 through September 2012 (Fig. 2),
including 250 VOCs with 247 analyzed after excluding three (one psy-
chiatric disorder and two non-SS or -S-β0thalassemia genotypes). One
hundred and forty-ﬁve patients were included once and 43 more than
once. Among patients who developed ACS and were included twice,
all but one had a VOC during the other hospitalization. Forty-four/41
(17.8%) ACSs occurred within 15 (median 3 [2, 3]) days post-admission
based on auscultation abnormalities and/or chest pain, but three pa-
tients were excluded from the analysis because ofmissing conﬁrmatory
chest radiographs. Only 2/41 chest radiograph-conﬁrmed ACSs did not
have an auscultatory abnormality. One VOC-group patient developed a
late ACS 20 days post-hospitalization.
Between-group clinical characteristics and SCD history at inclusion
(Table 1) were comparable, except for the precipitating factor during
the preceding 3 days. Patients were equally treated with hydroxyurea.
VOC and ACS steady-state biological parameters for 222 episodes were
comparable for the two groups, except red blood-cell (RBC) counts, re-
spectively: 3.2 ± 0.7 × 1012/L and 2.9 ± 0.5 × 1012/L (p= 0.02).
A factor precipitating 186/203 (91.6%) VOCs and 34/41 (82.9%) ACSs
was identiﬁed, with ≥2 for 92/203 (45.3%) and 18/41 (43.9%), respec-
tively. The most frequent precipitating factors were cold (39·7%; signif-
icantly more frequent for VOCs; p = 0.004), exertion (31.1%), stress
(23.4%), physician-suspected infection (20%), menstruation (14.9%)
and decreased oral hydration (13.1%).
The mean VOC-onset-to-arrival (Table 2) interval was ~1 day; pain
appeared at night for ~25% of the patients with no between-group dif-
ferences. SpO2 was b96% in 9.8% of VOC and 19.5% of ACS patients
(p=0.04). Despite similar respiratory frequency values, tachypnea (N-
20 breaths/min) was more frequent in ACS (39% vs 29.1% in VOC; p =0.001). The mean VAS-assessed global pain intensity and total CPS
were comparable, but ACS patients had signiﬁcantly more intense
S ± P (Table 3, Fig. 1) and milder left arm pain. Pain intensity in the
ﬁve other body sites, including chest, was similar for both groups. Ac-
cording to univariate analyses, ACS patients' leukocyte, neutrophil and
reticulocyte counts, and LDH, direct bilirubin, aspartate aminotransfer-
ase, alkaline phosphatase and C-reactive protein levelswere signiﬁcant-
ly higher, but their RBC counts and hemoglobin levels were lower than
those of VOC patients.
3.2. Scores
Multivariate analyses retained day-1 N 216 × 109 reticulocytes,
N11× 109 leukocytes and S± P CPS=2 or 3 as being independently as-
sociated with ACS. The model was adjusted to hemoglobin ≤ or N9 g/dL
(Table 3). Theﬁnal score is the sumof the points accorded those four pa-
rameters; it was unchanged when adjusted for hydroxyurea. A score
predicting ACS, calculated by adding the transformed β-coefﬁcients
for the 226 (189 VOC and 37 ACS) patients with no missing data for
the parameters, ranged between 0 and 16.
The AUROC was 0.836 [0.773–0.898] (Supplementary ﬁg. S1). The
ROC curve determined two cutoffs, yielding three ACS-risk groups,
each representing a third of the patients: score ≤ 5 (n = 89): low,
with NPV = 98.9% (88/89); score N 11 (n = 47): high, with positive-
predictive value (PPV) = 44.7% (21/47); and score 6–10 (n= 90): in-
termediate NPV = 83.3% and PPV= 16.7% (75/90) (Table 3). Applying
the ACS-predictive score to the study population would have missed
only 1/40 analyzable ACSs.
3.3. Outcomes
Median hospital stay was longer for ACS than VOC patients, respec-
tively: 9 [7–11] vs 4 [3–7] days (p b 0.0001). Seven/41 (17%) ACSs vs
1/203 (0.5%) VOC (p b 0.0001) patients required intensive care. No pa-
tient died. ACS patients required more BTs than VOC patients, respec-
tively: 20/41 (48.7%) vs 6/203 (3%) (p b 0.0001). For all but one (pre-
cholecystectomy) BT, ACS severity was the BT indication, according to
Fig. 2. Study ﬂow chart. VOC = vaso-occlusive crisis. ACS = acute chest syndrome.
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dian of 3 [2, 3] days. VOC patients were transfused at a median 8 [5–11]
days because of prolonged pain (3/6), late ACS on day 20 (1/6), severe
cytomegalovirus infection (1/6) or severe anemia and low reticulocyte
count (1/6).
Four/41 (9·7%) ACS vs 28/203 (13.8%) VOC (p= 0.4) patients were
readmittedwithin 2 weeks of discharge. ACS- or VOC-patientmorphine
consumptions on days 1 (Table 1), as thereafter on days 2 and 4 (for 36
ACSs and 113 VOCs; p= 0.5), were comparable. At inclusion, only 7.3%
of ACS and 3.9% of VOC patients were febrile (p = 0.64), with the
former's mean temperature being slightly higher (p = 0.05). Their
hemocultures and CBEU were negative; colchicine attenuated one
patient's wrist arthritis and another had valganciclovir-treated cyto-
megalovirus infection with cytolytic hepatitis. Throughout hospitaliza-
tion, 12 (29%) of the 41 ACS patients were febrile, all were Legionella-
and streptococcal pneumonia urinary antigen-negative; amoxicillin
was prescribed for all but one and 6/12 also received a macrolide.
4. Discussion
VOC is themain cause of SCD-patient Emergency-Department arriv-
al and ACS is one of its most severe complications, especially in adults,
with high morbidity and mortality (Platt et al., 1994; Perronne et al.,2002; Maitre et al., 2000; Castro et al., 1994; Mekontso Dessap et al.,
2008). ACS occurred in ~50% of hospitalized VOC patients a mean of
2.5 days post-admission (Vichinsky et al., 2000), similar to the
2.8 days herein (median: 3 days). A recent American epidemiological
study (Hamideh and Alvarez, 2013) found higher mortality rates
among rural SCD patients than their urban counterparts, highlighting
the need to improve rural medical care. No biological or clinical marker
predictive of developing ACS was previously available.
Our results enabled construction of a very simple ACS-predictive
score based on four day-1 parameters (i.e., reticulocyte and leukocyte
counts, hemoglobin and S± P CPS). It has excellent NPV, enabling iden-
tiﬁcation, as of Emergency-Department admission for VOC, of patients
at very low or high risk (one-third each) of developing ACS. When ap-
plied routinely, this score enables emergency-care physicians to orient
the former towards short hospital stays or outpatient monitoring, as
in many African countries, and to transfer the latter to referral centers
where ACS-preventive therapy-intensiﬁcation protocols can be applied.
Indeed, therapeutic trials primarily aimed at lowering the ACS rate dur-
ing VOC, based on the score to select patients at risk, would bemore ap-
propriate than the previous goal of shortening pain duration (Bartolucci
et al., 2009; Orringer et al., 2001) or hospital stays (Bernini et al., 1998),
or improving VOC resolution, as deﬁned by composite scores (Gladwin
et al., 2011). We emphasize that the score was determined during
Table 1
Characteristics of the 244 vaso-occlusive crisis (VOC) episodes at inclusion.
Characteristic VOCs ACSs p
Number (%) 203 (83.2) 41 (16.8)
Age, yr 27.7 ± 7.3 26.9 ± 6.5 0.52
Males, n (%) 101 (49.8) 22 (53.7) 0.65
Body mass index 21.4 ± 3.3 20.9 ± 2.9 0.43
Hydroxyurea treatment 66 (32.5) 15 (36.6) 0.61
SCD history
Transfusion during the last year 55 (27.1) 16 (36.4) 0.27
ICU admission during the last year 43 (21.2) 9 (20.5) 1
0 VOC hospitalizations/yeara 33 (16.3) 10 (22.7) 0.38
1–2 VOC hospitalizations/yeara 85 (41.9) 16 (36.4) 0.61
3–5 VOC hospitalizations/yeara 64 (31.5) 16 (36.4) 0.6
N5 VOC hospitalizations/yeara 21 (10.3) 2 (4.5) 0.39
Number of previous ACSs 1 [0–3] 1.5 [0–3] 0.61
Cerebral vasculopathy 7 (3.4) 1 (2.3) 1
Retinopathy 28 (13.8) 5 (11.4) 0.81
Kidney involvement 15 (7.4) 6 (13.6) 0.23
History of leg ulcer 17 (8.4) 1 (2.3) 0.21
Osteonecrosis 48 (23.6) 7 (15.9) 0.32
History of priapism 32 (31.7) 13 (54.2) 0.057
Precipitating factor in the past 3 days 186 (91.6) 37 (84.1) 0.16
Cold 89 (43.8) 8 (19.5) 0.005
Exertion 62 (30.5) 14 (31.8) 0.71
Stress 46 (22.7) 10 (24.4) 0.84
Infection (suspected) 39 (19.2) 10 (24.4) 0.52
Menstruation 16 (15.7) 3 (15.8) 1
Less oral hydration 27 (13.3) 4 (9.8) 0.80
Alcohol consumption 12 (5.9) 0 (0) 0.23
Vomiting or diarrhea 11 (5.4) 2 (4.9) 1
Steroids 2 (1) 2 (4.9) 0.13
Snoring 12 (5.9) 4 (9.8) 0.32
Limb compression 1 (0.5) 1 (2.4) 0.31
Airplane travel 1 (0.5) 0 (0) 1
Bold value indicates signiﬁcance at p b 0.05.
ACSs= secondary acute chest syndromes. SCD= sickle-cell disease. ICU= intensive care
unit.
Results are expressed as n (%) or mean ± SD or median [IQR].
a Mean number of VOC hospitalizations/patient/year for during the last 3 years.
Table 2
Clinical and biological parameters at Emergency-Room arrival.
Parameter VOCs ACSs p Missing
Number (%) 203 (83.2) 41 (16.8)
VOC-onset-to-hospitalization
interval (h)
22 [14–36] 21 [14–310] 0.55 11
VOC night appearance 45 (22.2) 11 (26.8) 0.52 0
Temperature (°C) 36.9
[36.5–37.2]
36.9
[36.7–37.3]
0.092 20
Transcutaneous O2 saturation (%) 99 [97–100] 98.5
[95–100]
0.17 11
Breaths/min 18 [16–20] 20 [16–25] 0.041 70
Systolic blood pressure (mm Hg) 122
[110–135]
123
[111–135]
0.47 18
Diastolic blood pressure (mm
Hg)
70 [62–80] 69 [64–78] 0.76 18
Arrival pain VAS (mm) 8 [7–9] 8 [7–10] 0.25 6
CPS sums for the 7 body parts 5 [4–8] 7 [5–12] 0.56 0
Spine and/or pelvis 1 [0–2] 2 [1–3] b0.001 3
Ribs and sternum 0 [0–1 0 [0–2] 0.155 3
Skull 0 [0–0] 0 [0–0] 0.705 3
Right upper limb 0 [0–2] 0 [0–1] 0.70 3
Left upper limb 0 [0–2] 0 [0–0] 0.023 3
Right lower limb 1 [0–2] 1 [0–2] 0.94 3
Left lower limb 0 [0–2] 1 [0–2] 0.686 3
Morphine consumption on day 1 42 [21–81] 56 [30–77.5] 0.3 19
Red blood cells (×1012/L) 3.0 [2.6–3.5] 2.7 [2.4–3.4] 0.017 1
Hemoglobin (g/dL) 9.1 [8.3–9.9] 8.2
[7.5–10.1]
0.023 0
White blood cells (×109/L) 11.3
[8.8–15.8]
16.3
[13.3–20.1]
b0.001 0
Neutrophils (×109/L) 6.8
[5.2–10.4]
8.6
[6.9–14.7]
0.011 36
Platelets (×109/L) 345
[280–412]
371
[282–395]
0.075 2
Reticulocytes (×109/L) 206
[158–253]
262
[232–343]
b0.001 16
Lactate dehydrogenase (IU/L) 397
[322–526]
501
[409–601]
0.001 3
Total bilirubin (μmol/L) 36 [25–54] 48 [33–76] 0.005 3
Direct bilirubin (μmol/L) 10 [7–13] 12 [9–17] 0.002 3
Indirect bilirubin (μmol/L) 25 [17–38] 34 [22–50 0.007 4
Aspartate aminotransferase
(IU/L)
39 [29–54] 53 [33–69] 0.02 5
Alanine aminotransferase (IU/L) 23 [16–36] 31 [16–50] 0.17 3
γ-Glutamyltransferase (IU/L) 43 [24–85] 47 [32–104] 0.11 7
Alkaline phosphatase (IU/L) 77 [60–104] 104
[80–129]
b0.001 5
Creatinine (μmol/L) 59 [47–69] 59 [47–68] 0.81 2
Blood urea nitrogen (mmol/L) 2.5 [1.8–3.1] 2.6 [2.1–3.3] 0.20 2
Creatine phosphokinase (IU/L) 58 [43–91] 67 [44–92] 0.46 29
C-reactive protein (mg/L) 15 [5–42] 35 [13–86] 0.001 20
Bold values indicate signiﬁcance at p b 0.05.
VOC, vaso-occlusive crisis; ACSs: secondary acute chest syndromes;Missing,missing data;
CPS, categorical pain score.
Results are expressed as n (%), mean ± SD or median [IQR].
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ever, it is unlikely that the score would be different if less severe VOCs
were included.
Because no consensual ACS deﬁnition exists, we used a deﬁnition re-
quiring chest radiograph. However, auscultation abnormality alone
should sufﬁce for ACS diagnosis, based on French guidelines and our
clinical practice. Crepitants and/or bronchial breathing occur earlier
than radiographic abnormality, and chest pain is not always present de-
spite severe ACS. The major advantage of a deﬁnition based on the ap-
pearance of those signs (but not other anomalies) is its broad
applicability, evenwhere radiography is expensive and/or not available,
as in many areas in Africa. Moreover, the onset of those signs should be
sufﬁcient to diagnose ACS.
Our ACS-predictive model's clinical parameter is S ± P pain. Spine
and pelvis trabecular bone characteristics probably explain ourﬁndings.
VAS does not locate pain, unlike our CPS that we used previously
(Bartolucci et al., 2009). Pain categorized at four levels and determined
for seven body parts was easily determined and discriminant. S± P “Se-
vere pain with disability” was the most frequent ACS criterion, while
“No pain” was the most frequent for uncomplicated VOC. Surprisingly,
chest pain at arrival did not differ but ~80% of ACS patients suffered
chest pain at its onset. Decreased respiratory frequency did not differ ei-
ther, whereas arrival SpO2was slightly lower for future ACS patients. In-
triguingly, cold was a less frequent precipitating factor for ACS patients,
perhaps because limb-bone vascular perfusion is more probably inﬂu-
enced by low temperature-induced vascular changes. Infections did
not differ between groups but have been associated with ACSs in chil-
dren and adults (Vichinsky et al., 2000). However, at arrival, our pa-
tients were rarely febrile and systematic hemocultures, CBEU, and
searches for Legionella and streptococcal pneumonia urinary antigens,when abnormal lung sounds were heard during hospitalization, were
negative. Chlamydia,Mycoplasma andHaemophiluswere not sought be-
cause such tests were not easily and routinely done during the investi-
gation period, and thus outside the study's scope.
Notably, the arrival reticulocyte count contributed strongly to the
predictive score, being signiﬁcantly higher on day 1 than at steady
state for 2°ACSs (272 ± 88 vs 237 ± 95, respectively p = 0.006, n =
33 paired values), while the VOC group's values were stable (p =
0.98). Moreover, increased reticulocyte adhesion to activated endothe-
lium and subendothelial matrix compounds (Hebbel, 1997; Swerlick
et al., 1993) was mainly attributed to more membrane-adhesion mole-
cules (El Nemer et al., 1998; Cartron and Elion, 2008), some of which
disappear on mature RBCs, e.g., α4β1 or CD36 (Swerlick et al., 1993;
Browne and Hebbel, 1996; Joneckis et al., 1993), and to functional sig-
naling pathways more active in reticulocytes than mature RBCs
(Bartolucci et al., 2010; Limbird et al., 1980). Leukocytes are the other
major score component. Their increase during VOCs has been proven;
Table 3
ACS-predictive model derived from the multivariate analysis.
Day-1 variable β-Coefﬁcient aOR [95% CI] p Pointsa
Reticulocytes (109/L)
≤216 0 1 0
N216 2.153 8.613 [3.01–24.69] b0.001 6
Spine and/or pelvis CPS 0
0 or 1 0 1
2 1.401 4.060 [1.46–11.26] 0.007 4
3 1.852 6.371 [2.37–17.15] b0.001 6
Leukocytes (109/L)
≤11 0 1 0
N11 1.160 3.190 [1.17–8.72] 0.024 3
Hemoglobin (g/dL)b
N9 0 1 0
≤9 0.246 1.279 [0.55–2.96 0.567 1
Predictive model performance on the study population
Predictive scorec ACSs VOCs Total Risk
≥11 21 26 47 PPV = 44.7% High
6–10 15 75 90 Intermediate
≤5 1 88 89 NPV = 98.9% Low
Total 37 189 226
aOR = adjusted odds ratio. CPS = categorical pain score. ACSs = secondary acute chest
syndromes. VOCs = vaso-occlusive crises. PPV = predictive-positive value. NPV =
negative-predictive value.
a Pointswere calculated bymultiplying themodel'sβ-coefﬁcients for each independent
parameter ×3 and rounded to the nearest integer (AUC= 0.836 [CI 0.773–0.898]).
b Forced into the model to adjust to the Hosmer–Lemeshow statistic = 0.967.
Nagelkerke R2 = 0.338.
c The ACS-predictive score is the sum of the points accorded each of the four day-1
variables.
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ACS and VOC than reticulocytes. Leukocytes are known to be an inde-
pendent factor predictive of SCD-associated death (Platt et al., 1994).
Reported results demonstrated enhanced leukocyte adhesion to SS
RBCs (Chaar et al., 2010) and vascular endothelium (Turhan et al.,
2002), and their subsequent leukocyte participation in vaso-occlusion
(Belcher et al., 2000; Hidalgo et al., 2009).
Pertinently, hydroxyurea did not modify the score, perhaps because
patients taking it have lower reticulocyte and leukocyte counts. Hence, a
reticulocyte or leukocyte rise under it would probably discriminate bet-
ter between groups thanwithout such increases. Furthermore, the com-
parable percentages of hydroxyurea-treated patients in our two groups
indicate that, when treated patients develop severe VOCs requiring hos-
pitalization, their risk of worsening is comparable to that of untreated
patients, which should not be confused with hydroxyurea's protective
effect against ACS and VOC (Charache et al., 1995). Because the hy-
droxyurea dose was not considered in this study, we could not exclude
a difference according to its dose. Morphine consumption on hospital
days 1, 2 and 4 did not differ between groups, thereby excluding its pos-
sible effect on ACS appearance, in contrast to previous hypotheses
(Kopecky et al., 2004; Buchanan et al., 2005).
Our study was homogenous because of its monocenter design with
the same physicians, biologists and guidelines for all patients. Our re-
sults enabled a score to be built that could bring new perspectives to
SCD management, but remains to be validated in other centers and
countries, and tested on pediatric populations, before concluding as to
its usefulness. In conclusion, a score predictingACS as of Emergency-De-
partment arrival for VOC, based on reticulocyte and leukocyte counts,
hemoglobin and S±P CPS, is simple enough to be easily applied and
could change VOC therapeutic perspectives.
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